Results 21 to 30 of about 7,679 (193)

Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study

Frontiers in Immunology, 2023
BackgroundEosinophilic granulomatosis with polyangiitis (EGPA) is a rare vasculitis characterized by asthma, systemic manifestations, and blood and tissue eosinophilia.ObjectiveTo assess the effectiveness and safety of mepolizumab (anti-IL-5) and ...
Santi Nolasco, Santi Nolasco, Andrea Portacci, Raffaele Campisi, Enrico Buonamico, Corrado Pelaia, Alida Benfante, Massimo Triggiani, Giuseppe Spadaro, Maria Filomena Caiaffa, Giulia Scioscia, Aikaterini Detoraki, Giuseppe Valenti, Francesco Papia, Alessandra Tomasello, Nunzio Crimi, Nicola Scichilone, Girolamo Pelaia, Giovanna Elisiana Carpagnano, Claudia Crimi, Claudia Crimi   +20 more
doaj   +1 more source

The role of ACT score in mepolizumab discontinuation [PDF]

, 2023
Mepolizumab is a therapy for severe asthma. We have little knowledge of the characteristics of people in the US that discontinue mepolizumab in clinical care.
Brittany Beck (17695896), Emily Pennington (17695905), Neha Solanki (17695893), Sumita Khatri (12800962), Stephanie King (551654), Kevin Smith (792017), Mark Aronica (747258), Monica Labadia (17695899), Sobia Farooq (17695908), Laura Peterson (10068490), Peng Zhang (2071), Sarah Micklewright (17695902), Serpil Erzurum (337322), Joe Zein (2806369), Suzy Comhair (337321)   +14 more
core   +1 more source

Use of Mepolizumab in Children and Adolescents with Asthma in the USA

Journal of Respiration, 2022
Introduction: Pediatric asthma affects 5.5 million US children and is the leading cause of pediatric chronic illness globally. Those with severe asthma have significantly higher healthcare costs compared to those with non-severe disease.
Jaclyn Davis, Pamela M. McMahon, Emily Welch, Cheryl McMahill-Walraven, Aziza Jamal-Allial, Tancy Zhang, Christine Draper, Anne Marie Kline, Leslie Koerner, Jeffrey S. Brown, Melissa Van Dyke, Ann Chen Wu   +11 more
doaj   +1 more source

Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry [PDF]

, 2021
BACKGROUND: Oral corticosteroids (OCS) carry serious health risks. Innovative treatment options are required to reduce excessive exposure and promote OCS stewardship.
Gibson, PG, Stevens, S, Katelaris, CH, Lee, J, Katsoulotos, GP, Bowler, S, Kritikos, V, Chung, LP, Grainge, C, Peters, M, Reynolds, PN, Wark, PAB, McDonald, VM, Jenkins, C, Farah, CS, Rimmer, J, Harvey, ES, Thomas, D, Upham, JW, Bowden, JJ, Harrington, J, Radhakrishna, N, Sivakumaran, P, Gillman, A, Chien, J, Langton, D, Baraket, M, Reddel, HK, Hew, M, Bardin, P   +29 more
core   +1 more source

Mepolizumab exerts crucial effects on glucocorticoid discontinuation in patients with eosinophilic granulomatosis with polyangiitis: a retrospective study of 27 cases at a single center in Japan

Arthritis Research & Therapy, 2023
Objectives To investigate the efficacy of mepolizumab in patients with eosinophilic granulomatosis with polyangiitis (EGPA) and factors contributing to glucocorticoid (GC) discontinuation.
Takashi Yamane, Akira Hashiramoto
doaj   +1 more source

Treatment of patients with the hypereosinophilic syndrome with mepolizumab. [PDF]

, 2008
BACKGROUND: The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause.
Parkin, Jacqueline M., Frewer, Paul I. H., Kahn, J.E., Rothenberg, Marc E., Parkin, Jacqueline M, Weller, Peter F., Roufosse, Florence E, Weller, Peter F, Klion, Amy D, Haig, Ann E, Schwartz, Lawrence B., Haig, Ann E., Rosenwasser, Lanny J, Rothenberg, Marc E, Schwartz, Lawrence B, Griffin, Elaine F, Frewer, Paul I H, Klion, Amy D., Roufosse, Florence, Ring, Johannes, Simon, Hans-Uwe, Rosenwasser, Lanny J., Kahn, Jean E., Griffin, Elaine F., Gleich, Gerald J, Roufosse, Florence E., Gleich, Gerald J., Kahn, Jean Emmanuel   +27 more
core   +4 more sources

Response to mepolizumab treatment is sustained across 4-weekly dosing periods

ERJ Open Research, 2020
Background Mepolizumab (100 mg delivered s.c. every 4 weeks) is indicated for add-on maintenance treatment for patients with severe eosinophilic asthma. Mepolizumab has been shown to reduce exacerbations and the requirement for daily oral corticosteroids,
Ian D. Pavord, Eugene R. Bleecker, Roland Buhl, Pascal Chanez, Elisabeth H. Bel, Peter Howarth, Daniel J. Bratton, Frank C. Albers, Steven Yancey   +8 more
doaj   +1 more source

REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils : The REDES Study [PDF]

, 2021
The efficacy of mepolizumab is well documented in severe eosinophilic asthma (SEA), although the stringent selection criteria adopted by SEA clinical trials limits the generalizability of results.
Bañas-Conejero, David, Carrillo Díaz, Teresa, Blanco-Aparicio, Marina, Sánchez Herrero, M. Guadalupe, Universitat Autònoma de Barcelona. Departament de Medicina, Domingo, Christian, Martínez Moragón, Eva   +6 more
core   +1 more source

Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients [PDF]

, 2020
Background: Patients with severe asthma not meeting the strict trial eligibility criteria for mepolizumab are now routinely treated with this biological in clinical practice, but it remains unclear whether these ineligible patients respond differently to
Richards, Levi B., Neerincx, Anne H., Sont, Jaap K., Brinke, Anneke Ten, Weersink, Els J. M., Bel, Elisabeth H. D., van Bragt, Job J. M. H., Braunstahl, Gert-Jan, Aarab, Reim, Longo, Cristina, Maitland-van der Zee, Anke-Hilse   +10 more
core   +4 more sources

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice [PDF]

, 2019
Background: Asthma is an inflammatory disease of the airways with symptoms that vary over time and intensity, sometimes leading to disability or even death. Eosinophilic asthma accounts for 25% of cases of severe asthma.
Olalla Montero-Pérez, Ernesto Sánchez-Gómez, María Beatriz Contreras-Rey   +2 more
core   +1 more source